Key result
Current American and European clinical guidelines recommend minimizing the duration of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention to reduce bleeding risks.
This review summarizes American and European guidelines on antithrombotic therapy for patients with AF undergoing PCI, emphasizing the role of clopidogrel in dual or triple therapy.
In this review are provided relevant positions of the American and European clinical guidelines for antithrombotic therapy in the patients with a combination of atrial fibrillation and coronary heart disease with percutaneous coronary intervention. Similarities and distinctions of positions of two expert communities were discussed. In addition, the evidence-based positions concerning the choice of the optimal antithrombotic therapy are noted. Primary positions of a clopidogrel when choosing the antiagregants for double or triple antithrombotic therapy were designated.
No takes yet. Share an insight, caveat, or question.
Барбараш et al. (2019) conducted a review in Atrial fibrillation and coronary heart disease with percutaneous coronary intervention. Antithrombotic therapy was evaluated. Current American and European clinical guidelines recommend minimizing the duration of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention to reduce bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: